Synthetic RNA–protein decoy granules prevent SARS-CoV-2 infection

Synthetic phase-separated RNA–protein granules, displaying soluble human angiotensin-converting enzyme-2 receptor, act as stable decoy targets that inhibit Delta and Omicron entry at low micromolar doses, outperforming soluble angiotensin-converting enzyme-2, while remaining functional over several days in biological media, offering a modular, pan-variant antiviral platform for prophylaxis and broad-spectrum potential for future pandemics.